Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 7, 2014; 20(25): 8055-8060
Published online Jul 7, 2014. doi: 10.3748/wjg.v20.i25.8055
Published online Jul 7, 2014. doi: 10.3748/wjg.v20.i25.8055
Peroxisome proliferator-activated receptor α, a potential therapeutic target for alcoholic liver disease
Yue-Min Nan, Rong-Qi Wang, Na Fu, Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang 050051, Hebei Province, China
Author contributions: Fu N searched the literature; Nan YM prepared the paper; Wang RQ edited this manuscript.
Correspondence to: Yue-Min Nan, MD, PhD, Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, 139 Ziqiang Road, Shijiazhuang 050051, Hebei Province, China. nanyuemin@163.com
Telephone: +86-311-66781227 Fax: +86-311-87023626
Received: October 28, 2013
Revised: January 22, 2014
Accepted: March 12, 2014
Published online: July 7, 2014
Revised: January 22, 2014
Accepted: March 12, 2014
Published online: July 7, 2014
Core Tip
Core tip: Alcoholic liver disease (ALD) is among the most common chronic liver disease. Modulation of therapeutic genes could potentially provide a novel and more effective treatment option. In this paper, we summarized the potential therapeutic role of PPARα modulation and illustrated the mechanism of PPARα in modulation of hepatic lipid metabolism, oxidative stress, inflammatory response and fibrogenesis in alcoholic liver disease. It is identified that PPARα agonists may serve as an effective therapeutic strategy for ALD.